Cargando…
The Contribution of Drugs and Helicobacter pylori to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome
BACKGROUND: The nature and rate of gastric mucosal (GM) damage in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) remain to be among the unsolved problems. OBJECTIVE: To define the role of H. pylori and drugs in the development of GM damages in SLE and APS. METHODS: A study wa...
Autores principales: | Reshetnyak, Tatiana M., Doroshkevich, Irina A., Seredavkina, Natalia V., Nasonov, Evgeny L., Maev, Igor V., Reshetnyak, Vasiliy I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525898/ https://www.ncbi.nlm.nih.gov/pubmed/31191660 http://dx.doi.org/10.1155/2019/9698086 |
Ejemplares similares
-
IgA Antiphospholipid Antibodies in Antiphospholipid Syndrome and Systemic Lupus Erythematosus
por: Reshetnyak, Tatiana, et al.
Publicado: (2022) -
Markers of NETosis in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome
por: Reshetnyak, Tatiana, et al.
Publicado: (2023) -
Significance of dormant forms of Helicobacter pylori in ulcerogenesis
por: Reshetnyak, Vasiliy Ivanovich, et al.
Publicado: (2017) -
Helicobacter pylori: Commensal, symbiont or pathogen?
por: Reshetnyak, Vasiliy Ivanovich, et al.
Publicado: (2021) -
The Role of Neutrophil Extracellular Traps (NETs) in the Pathogenesis of Systemic Lupus Erythematosus and Antiphospholipid Syndrome
por: Reshetnyak, Tatiana, et al.
Publicado: (2023)